Linagliptin's Effect on CD34+ Stem Cells

NCT02467478 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

31

Enrollment

OTHER

Sponsor class

Conditions

Type 2 Diabetes
Impaired Renal Function

Interventions

DRUG: Linagliptin
DRUG: Placebo

Sponsor

George Washington University

Collaborators

[object Object]